Simulations Plus Inc. on Thursday announced it has entered into a collaborative agreement with Bayer AG to advance its ADMET Predictor, a software program used for drug discovery workflows.
The Lancaster drug simulation business will use input from Bayer to further develop software for use in specifically designed drug discovery platforms.
The ADMET product, which stands for absorption, distribution, metabolism, excretion and toxicity, helps scientists predict more than 140 drug properties.
“We have partnered with Bayer on several scientific projects in the past and are pleased to announce this new collaboration supporting machine learning in drug discovery,” David Miller, director of ADMET cheminformatics at Simulations Plus, said in a statement. “With so many packages used in large pharmaceutical R&D organizations, it is important to ensure data integrity and prevent information loss across platforms.”
Shares of Simulation Plus (SLP) closed Thursday down 3 cents, or less than a percent, to $32.51 on the Nasdaq.